ABSTRACT
Objective To investigate the relationship between peripheral inflammatory cytokines and anxiety symptoms in patients with the first?episode generalized anxiety disorder. Methods 48 patients diagnosed with the first?episode generalized anxiety disorder according to ICD?10 criteria and 48 healthy sub?jects were recruited. Peripheral levels of IL?1, IL?2, IL?4, IL?5, IL?6, IL?8, IL?10, IL?12p70, GM?CSF and IFN?γ of both groups were evaluated by enzyme?linked immunosorbent assay ( ELISA) ,and CRP was evalua?ted by immunoturbidimetric method. Generalized Anxiety Disorder Scale( GAD?7) and State?Trait Anxiety Inventory ( STAI ) were used to assess the levels of overall anxiety, state anxiety and trait anxiety. Results The levels of CRP ( ( 1. 19 ± 0. 80 ) mg/L vs ( 0. 68 ± 0. 70 ) mg/L, t=3. 31 ) , IL?1α( ( 70. 34 ± 3.60)pg/ml vs (16.94±3.42)pg/ml, t=74.50),IL?2((7.25±3.42)pg/ml vs (4.95±2.31)pg/ml, t=3.85), IL?4((102.02±73.14)pg/ml vs (75.55±32.78)pg/ml, t=2.29),IL?6((12.55±2.37)pg/ml vs (2.71±1.35) pg/ml, t=14.79),IL?8((44.64±16.21)pg/ml vs (35.69±11.70)pg/ml, t=3.10),IL?12((18.16±24.17) pg/ml vs (10.82±4.72)pg/ml, t=2.06),IFN?γ((23.32±15.52)pg/ml vs (16.48±6.80)pg/ml, t=2.79), GM?CSF((19.07±11.12)pg/ml vs (13.40±8.54)pg/ml, t=2.80) in patients with the first?episode general?ized anxiety disorder were significantly higher than normal controls(P<0.05) . Both SAI and TAI had signifi? cantly positive correlation with the levels of IL?1α, IL?2, IL?6, IL?8, IL?12, IFN?γ and GM?CSF ( r=0.24?0.76, P<0.05) . Conclusion The levels of some peripheral inflammatory cytokines in patients with the first?episode generalized anxiety disorder are significantly increased,and they have positive correlation with gener?al anxiety,state anxiety and trait anxiety,which may suggest some immune system defects in the patients.
ABSTRACT
The first aim of this study was to compare the serum thyroglobulin (Tg) positive rate between differentiated thyroid carcinoma (DTC) patients with positive thyroglobulin antibody (TgAb) and patients with negative TgAb. The second aim of this study was to investigate the correlation between serum Tg value and antithyroglobulin (TgAb) concentration of patients with DTC. We collected the serum Tg value and TgAb concentration of patients with DTC after thyroid ablation by operation and radioiodine therapy retrospectively. Then we investigated the Tg positive rate of DTC patients with positive TgAb and patients with negative TgAb separately. The scatter diagram between serum Tg value and TgAb concentration of DTC patients was performed to analyze their potential relationship. As a result, among 252 patients with DTC after thyroid ablation, 7 of 47 patients (14.89%) with positive TgAb (>115 IU/mL) had positive serum Tg (>10 microg/L), and 61 of 205 (29.76%) patients with negative TgAb (<115 IU/mL) had positive serum Tg. Eighty three of the 252 patients with DTC had accurate serum Tg and TgAb concentration. No correlation between serum Tg value and TgAb concentration was found among these Eighty three patients. Thus, it may be concluded that positive TgAb could cause much more TgAb interference in serum Tg value than negative TgAb could because of a different quality of TgAb. Serum Tg value is not correlated with serum TgAb concentration in patients with DTC after thyroid ablation.
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Autoantibodies , Blood , Carcinoma , Blood , Allergy and Immunology , Pathology , Thyroglobulin , Blood , Thyroid Neoplasms , Blood , Allergy and Immunology , PathologyABSTRACT
The aim of this study was to assess the role of 131 I-L-tyrosine for diagnosing E. coli infection and differentiating the infection from the inflammary lesion in mice. The L-tyrosine was labeled with 125 I by N-bromosuccinimide. The binding rates of 125 I-L-tyrosine with E. coli were tested by culturing E. coli with 125 I-L-tyrosine in poor nitrogen yeast medium and in rich nitrogen LB medium separately. The bio-distribution of 125 I-L-tyrosine and the 131 I-L-tyrosine SPECT scintigraphy in E. coli infection of mice were studied separately. The results revealed that the label rate of 125 I-L-tyrosine was more than 99%. The percentage of 125 I-L-tyrosine binding with E. coli was 2.78% in yeast medium, and was 0.85% in LB medium. The distribution peak of 125 I-L-tyrosine in E. coli focal infection of mice was in the range between 45 and 60 min. The infection/normal muscle ratio was 2.46 after 60 minutes. The SPECT scintigraphy demonstrated an accumulation of the 131 I-L-tyrosine in the E. coli focal infection during the 45-60 minutes. The infection/normal muscle ratio of the 131 I-L-tyrosine radioactivity was 2.51 in infectious mouse. However, the SPECT scintigraphy also demonstrated an accumulation of the 131 I-L-tyrosine in the inflammatory lesion during the 45-60 minutes. The lesion/normal muscle ratio of the 131 I-L-tyrosine radioactivity was 2.29 in inflammatory mouse at 60 mins. Thus, the 131 I-L-tyrosine SPECT scintigraphy could diagnose the E. coli infection, but it can not be used for differentiating the bacteria infection and the inflammatory lesion in mice. Our study revealed that the 131 I-L-tyrosine would play a potential role in diagnosing the inflammatory lesion in human beings.
Subject(s)
Animals , Mice , Diagnosis, Differential , Escherichia coli Infections , Diagnostic Imaging , Inflammation , Diagnostic Imaging , Iodine Radioisotopes , Tomography, Emission-Computed, Single-Photon , Methods , TyrosineABSTRACT
Objective To assess the variation of salivary gland function in differentiated thyroid carcinoma (DTC) patients receiving different doses of 131 I therapy in the first.Methods 40 DTC patients were divided into two groups according to the application 131I doses,salivary scintigraphy was performed with 99TcmO4-on DTC patients before and 3months after 131 I therapy.Quantitative analysis of salivary gland function were performed.Results In low dose group,only the uptake ratio of 30min (UR30) of bilateral parotid decreased ( P ＜ 0.05 ) ; but in high - dose group,the uptake ratio of 30min (UR30),excretion fraction ( EF ),excretion rate (ER) of bilateral parotid and submandibular glands were significantly decreased,excretion time(EP) significantly prolonged after 131 I therapy( all P ＜0.05) ;the parotid gland was more severely than the submandibular gland.Conclusion Salivary gland function was damaged of DTC patients receiving different doses of 131I therapy in the first,salivary gland dysfunction correlated well with the administered dose.
ABSTRACT
Objective To evaluate efficacy and clinical feasibility of 125Ⅰ combined with high intensity focused ultrasound(HIFU)therapy for hepatocellular carcinoma.Methods.The study included 10 cases of hepatocellular carcinoma(primary hepatic carcinoma,5 cases.Tumor recurrence of hepatocelluhr carcinoma after hepatecomy,5 cases).All the cases were treated with 125I combined with HIFU.Resultsl The operationWas successfully completed in all the cases.No severe post-operative complication occurred.CT acall found no displacement of 125Ⅰ seeds.CT 8can showed that reduced size of tmnor changed in different degree.The l month,3 month,6 month and l year survival cases were 8,7,5 and 2.During 3 to 18 months follow up,2 cases died within 1 month.Two cases survived more than 22 months.Conclusion Using 125Ⅰ combined with HIFU is safe,minimally invasive and effective for treatment of hepatocellular careinom.
ABSTRACT
<p><b>BACKGROUND</b>To study the clinical effects of ¹⁵³Sm-EDTMP plus chemotherapy in the treatment of bone metastasis of lung cancer.</p><p><b>METHODS</b>One hundred and ten lung cancer patients with one metastasis [male 82 and female 28, aged from 32 to 76 yrs; squamous cell carcinoma 28, adenocarcinoma 27, small cell lung cancer (SCLC) 7, mix type 41, alveolar carcinoma 7] who did not undergo an operation were entered into this study. The patients were divided into 3 groups: ¹⁵³Sm-EDTMP therapy only (37 cases), ¹⁵³Sm-EDTMP plus chemotherapy after 3 days (42 cases), 30 days after chemotherapy plus ¹⁵³Sm-EDTMP (31 cases). The dosages of ¹⁵³Sm-EDTMP ranged from 1 111 to 2 660 MBq. The patients with SCLC were adapted CCNU, MTX and CTX; those with non-small cell lung cancer (NSCLC) were adapted MMC, VCR and DDP. Statistic analysis of the data was performed by Chi-square test.</p><p><b>RESULTS</b>Total pain relief rate for ¹⁵³Sm-EDTMP only was 89.2% , for ¹⁵³Sm-EDTMP plus chemotherapy was 92.8%, and for chemotherapy plus 153 Sm EDTMP was 90.3% . The foci disappeared in 9 cases with ¹⁵³Sm-EDTMP only, in 12 cases with ¹⁵³Sm-EDTMP plus chemotherapy, and in 9 cases with chemotherapy plus ¹⁵³Sm-EDTMP. The 1 year survival rate was 29.7%(11/37) by 153 Sm only, 40.5%(17/42) by 153 Sm plus chemotherapy, 38.7%(12/31) by chemotherapy plus ¹⁵³Sm-EDTMP.</p><p><b>CONCLUSIONS</b>¹⁵³Sm-EDTMP plus chemotherapy is effective in the treatment of bone metastasis of lung cancer.</p>
ABSTRACT
The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation [I-131 Na], external beam radiation therapy [EBRT] and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of 153 patients [102, 51], age range 10-96 years, mean age 50.2 years treated for thyroid carcinoma. The range of follow-up was 1.0-294 months with median follow-up for 60.4 months. Twenty patients without therapy were excluded. Group A included 87 patients treated with I-131. Group B consisted of 13 patients received EBRT. Group C included both therapies in 33 patients. The therapies in all different stages of thyroid carcinoma and with various histopathologies were reviewed